logo
Share SHARE
FONT-SIZE Plus   Neg

VIVUS's Obesity Drug Rejected Again By European Medicines Agency

VIVUS Inc. (VVUS) announced that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP confirmed its October 18, 2012 decision to decline the Marketing Authorization Application or MAA for Qsiva (phentermine/topiramate ER) for the treatment of obesity in the European Union.

VIVUS had requested a re-examination of the opinion. After considering the grounds for this request, CHMP again declined the marketing authorization on February 21, 2013.

In its consideration of the Qsiva MAA, CHMP indicated that a pre-approval cardiovascular outcomes trial would be necessary to establish long-term safety.

Qsiva was approved by the U.S. FDA in July 2012 and is sold under the trade name Qsymia. The pivotal Phase 3 clinical trial program included over 4,500 subjects studied up to two years, establishing Qsymia as a safe and effective treatment for obesity.

Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Senator Lisa Murkowski, R-Alaska, has expressed support for repealing Obamacare's individual mandate, a key provision Senate Republicans are hoping to use to offset the cost of their tax reform bill. The Congressional Budget Office estimates repealing the requirement that nearly all Americans purchase... Automotive startup Divergent 3D said that a Chinese-led investment syndicate has agreed to commit up to $107 million in financing through a new investment round. Hong Kong-based investment holding company, O Luxe Holdings Limited, led the investment group, which includes Horizons Ventures, Shanghai Alliance Investment Limited and Altran Technologies. Apple Inc. has recently acquired Canada-based startup Vrvana, maker of the Totem augmented reality headset, TechCrunch reported. Both the companies reportedly declined to confirm news about the deal, which is reportedly worth $30 million.
comments powered by Disqus
Follow RTT